PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Items 301–400 of 538
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Manti, R., Cosmo, S. D., Desenzani, P., Ferrara, L., Girelli, A., Memoli, G., Bisio, A., Braae, U. C., Deinega, A., Berra, C., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01719-6 · Cited by 9
Self-citationWon, H., Cho, J., & Lee, S. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e3 · Cited by 8
“In PIONEER 1 (n = 703), oral semaglutide at doses of 3, 7, and 14 mg demonstrated significant reductions in HbA 1c and body weight compared to placebo in patients managed with diet and exercise [22].”
Dungan, K. M., Bardtrum, L., Christiansen, E., Eliasson, J., Mellbin, L., Woo, V. C., & Vilsbøll, T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01413-5 · Cited by 10
Self-citationPark, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
Essop, T., Tran, K., Purdy, A. C., & Daly, S. C. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01554-2 · Cited by 7
“Of the 9 studies evaluating GLP-1 agonists, 7 studies had follow-up intervals of less than 1 year [18–21, 23, 25], 1 study had a follow-up interval of 1 year [22], and 1 study had a follow-up interval of 15 months [24].”
Chandra, A. A., Espiche, C., Maliha, M., Virani, S. S., Blumenthal, R. S., Rodríguez, F., Wong, N. D., Gulati, M., Slipczuk, L. N., & Shapiro, M. D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100919 · Cited by 7
“Trials such as SURMOUNT and PIONEER have shown GLP-1 RA can lead to significant reductions in systolic blood pressure, primarily through weight loss [55,58,59].”
Costa, S., Miranda, C., Elefante, A., Vallone, V., Vinci, C., Borroni, F., Brandoni, G., Labate, A. M. M., Pomo, F. L., & Strazzabosco, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16314 · Cited by 7
“18 28 The drug was found to be safe and effective in reducing glycated haemoglobin (HbA1c) and, in a dose-dependent manner, body weight, 19 – 28 demonstrating superiority compared with placebo 19,22,23,26,27 and other active comparators.”
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16337 · Cited by 9
“28 – 34 In the SURPASS-3 and SURPASS-4 trials, participants randomized to insulin were titrated to a target fasting blood glucose ( 90 mg/dL [5 mmol/L] and 100 mg/dL [6 mmol/L], respectively) following a treat-to-target algorithm.”
Self-citationElangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Sabbagh, M. N., Boschini, C., Cohen, S., Fugger, M., Jessen, F., Dandanell, S., Pedersen, S. D., Tarazona, L. R. S., & Aroda, V. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70076 · Cited by 9
Self-citationDesai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01835-y · Cited by 7
Lu, W., Tian, H., Qian, P., Li, Y., Wang, Y., Ge, Y., Sai, W., Gao, X., & Yao, W. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15069 · Cited by 7
“Phase IIIa clinical data showed that the level of HbA1c decreased by 1.4% in patients after 26 weeks of oral semaglutide treatment (Aroda et al., 2019).”
BackgroundInfluentialJoshi, S., Rajput, R., Chowdhury, S., Singh, A. K., Bantwal, G., Das, A. K., Unnikrishnan, A., Saboo, B., Kesavadev, J., Ghosal, S., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102508 · Cited by 8
Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes
Scheen, A. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30079-6 · Cited by 7
Rethinking the intention-to-treat principle: one size does not fit all
Rengerink, K. O., Mitroiu, M., Teerenstra, S., Pétavy, F., & Roes, K. C. B. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.023 · Cited by 7
Miyasaka, K. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.21052 · Cited by 9
Fazioli, K., Rind, D. M., Guzauskas, G. F., Hansen, R. N., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1072 · Cited by 7
“We included evidence from 12 randomized controlled trials (RCTs).(8-19) Eight RCTs were part of PIONEER, a phase 3 clinical development program for oral semaglutide, including 1 CVOT.”
BackgroundMethodTirzepatide and the new era of twincretins for diabetes
Tan, T., & Khoo, B. C. E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01390-8 · Cited by 7
Lanius, V., Glocker, B., Christian, L., Bratton, D. J., Callegari, F., Wright, M., & Rajamäki, S. (2025) · Trials · doi:10.1186/s13063-025-08915-6 · Cited by 6
“(c) The underlying key idea of the estimand, e.g., Effect without Treatment discontinuation or Rescue Medication (Trial Product Estimand was used in [18]) or other context-related information such as, e.g., CHMP Guideline Effect (Committee for Medicinal 1) This assumption is generally not realistic…”
Chen, J.-J., Hsu, C., Hung, C., Suen, M.-W., Wang, H.-Y., Yang, W.-C., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020608 · Cited by 7
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
Delgado, E., Morales, C., Abreu, C., Verdugo, A. A., Carbonell, A. M. P., González, A. C., Valero, J. A. G., López, V. G., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16523 · Cited by 6
Marqués, M., Sánchez, P. L., Briales, P. S., Illazquez, M. V. L., & Portolés, J. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175166 · Cited by 6
“SNAC enhances the absorption of semaglutide through the stomach lining, effectively allowing for oral administration of this GLP-1 RA [14].”
BackgroundJoshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
“Within this program, eight multinational trials (PIONEER 1 – 8) were carried out [51 – 58] , and two more trials were conducted in Japan (PIONEER 9 and 10) [59,60] .”
Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Bissonnette, R., Eichenfield, L. F., Simpson, E. L., Thaçi, D., Kabashima, K., Thyssen, J. P., Guttman‐Yassky, E., Nunes, F. P., Gamalo, M., Ahmad, F., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18881 · Cited by 7
Oral semaglutide: the innovation in type 2 diabetes management
Shestakova, M. V., Шамхалова, М. Ш., Galstyan, G. R., Ruyatkina, L. A., & Суплотова, Л. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12790 · Cited by 6
Self-citationBhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5
Wang, T., Cui, Y., & Liao, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01689-1 · Cited by 5
“A total of ten articles were incorporated into the meta-analysis, encompassing 7817 participants (2947 Asian patients and 4870 non-Asian patients), with study durations varying from 26 to 78 weeks [10–19].”
Ali, A., Siddiqui, A. A., Usman, M., Shahid, I., Khan, M. S., & Perswani, P. (2025) · Clinical Obesity · doi:10.1111/cob.70012 · Cited by 5
Palazzi, S., Sentinelli, F., Zugaro, A., Morgante, S. N., Santarelli, L., Melanzi, S., Mutiis, A. D., Piersanti, D., Macerola, B., Iezzi, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060856 · Cited by 5
“…10.000 individuals with type 2 diabetes (T2D), has consistently demonstrated the efficacy of oral semaglutide in improving glycemic control, reducing body weight (BW), controlling CV risk factors such as blood pressure, lipid profile, and inflammation markers, and ensuring drug safety [4–13].”
InfluentialPonzo, V., Vitale, M., Bo, S., Broglio, F., Goitre, I., & Cioffi, I. (2025) · Nutrients · doi:10.3390/nu17213318 · Cited by 6
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
“Second, this study did not assess cause-specific outcomes such as cardiovascular death or hospitalization for HF, which are clinically important for addressing the research question.”
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
“Additionally, the currently approved dose (14 mg) has demonstrated modest weight loss relative to injectable semaglutide [15].”
Hara, T., Fujishima, Y., Kimura, Y., Fujii, K., Kawachi, Y., Nagao, H., Obata, Y., Fukuda, S., Nagai, N., Nishizawa, H., et al. (2026) · Endocrine Journal · doi:10.1507/endocrj.ej25-0402 · Cited by 5
Forzano, I., Narciso, V., Canonico, M. E., Castiello, D. S., Florimonte, D., Manzi, L., Semplice, F., Vallone, D. M., Cristiano, S., Spinelli, A. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031108 · Cited by 5
“Notably, semaglutide is the first GLP-1RA available for oral administration [83].”
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
“As a result, the Phase 3 dataset provides no direct clinical evidence regarding the efficacy, safety, or endocrine effects of oral semaglutide in PCOS [51–61].”
Peptide drugs application in metabolic diseases and discovery strategies
Bin, T. E. N. G., Junfeng, L. I., & Ren, P. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00063-8 · Cited by 7
Nomoto, H., Furusawa, S., Yokoyama, H., Suzuki, Y., Izumihara, R., Oe, Y., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae213 · Cited by 5
Inokuchi, T., Fukumoto, Y., Lee, G., 横溝由史, Tanaka, K., Chosa, M., Doi, M., Tamaki, N., Goto, S., Ichikawa, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14225 · Cited by 5
Novel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Miyazaki, R., & Miyagi, K. (2023) · Renal Replacement Therapy · doi:10.1186/s41100-023-00492-1 · Cited by 5
Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study
Ray, S., Ray, A., Goutam, S., & Mitra, A. (2024) · Clinical Diabetology · doi:10.5603/cd.102374 · Cited by 5
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
Karásek, D. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.018 · Cited by 8
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
Martens, P., Mathieu, C., & Vanassche, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2076307 · Cited by 5
“However, GLP-1RA also has a direct anti-inflammatory effect, as illustrated by the reduction in C-reactive protein in clinical trials [9,25,26].”
BackgroundGlucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Sato, G. E., Uchino, H., & Hirose, T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01631-5 · Cited by 4
Oral GLP-1 Receptor Agonists for Weight Loss
Krinsky, D., Marcucci, A., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000833 · Cited by 4
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Alromaih, A., Alshamrani, A., Alharbi, B., Alharbi, I., Alharbi, T., Bokhari, S., Elbadawi, H., Almehthel, M. S., Alsaeed, A. H., Alyahia, K., et al. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132017 · Cited by 4
Bhattacharyya, S., Saboo, B., Mohit, M., Bhojane, S., Deshmane, R., Chavda, V., Hasnani, D., Jagadeesha, A., & Sikdar, M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_15_23 · Cited by 4
Deng, R., Mei, K., Song, T., Huang, J., Wu, Y., Yu, P., Yan, Z., & Liu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1289643 · Cited by 4
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202405.0258.v1 · Cited by 4
Dayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Alfaifi, M., Alghadeer, S. M., & Alwhaibi, A. M. (2025) · Healthcare · doi:10.3390/healthcare13151827 · Cited by 4
“…secretion, and slow the digestive process via modulating the GLP-1 signaling pathway, semaglutide began to be manufactured by Novo Nordisk [2] and was approved first as a subcutaneous injection (Ozempic ® ) and then as an oral tablet (Rebylsus ® ) for glycemic control in adults with T2DM [3,4].”
Sanyal, D., Saboo, B., Phatak, S., Kumar, P. K. M., Basu, D., Verma, N., NAIR, A., Bhattacharjee, K., Aneja, P., Makkar, B. M., et al. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_179_25 · Cited by 3
D’Amico, C., Jacques, B., Ferdon, R. J., Silvestre, J., Lewis, S., Nielsen, C. J., Glaser, J. A., Reitman, C. A., Lawrence, J. P., & Ravinsky, R. A. (2026) · Asian Spine Journal · doi:10.31616/asj.2025.0407 · Cited by 3
“Although these reductions in readmission and infection rates align with our findings, only one GLP-1A was studied, and previous clinical studies have shown slightly different mechanisms among GLP-1As available on the market [5,7].”
Prasad, A., Arora, A., Arora, A., Vaid, J., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70515 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
“As a result, oral formulations are best viewed as an expansion of the therapeutic toolkit rather than direct substitutes for injectable agents [192].”
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
“Its efficacy was comparable or superior to other GLP-1RAs, including liraglutide and dulaglutide, and clearly exceeded placebo, demonstrating its effectiveness across different populations and treatment regimens [36–39].”
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Gliozzi, M., Coppoletta, A. R., Cardamone, A., Carresi, C., Mollace, R., Musolino, V., & Mollace, V. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107744 · Cited by 3
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
“The PIONEER program, which included extensive phase 3 clinical trials, demonstrated that oral semaglutide is non-inferior to placebo in terms of cardiovascular safety and leads to significant improvements in blood glucose control, BW, BMI, and WC [15,17,24–32].”
Je, I., Kim, T.-K., Lee, M. Y., Lee, M.-Y., An, K., Park, J.-T., & Kim, K.-Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178143 · Cited by 3
Self-citationWANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 4
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. II. Kezelés
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
“A per os készítmény [29] hamarosan ha-zánkban is forgalomba kerülhet.”
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
Takahara, M., Shiraiwa, T., Katakami, N., Maeno, Y., Yamamoto, K., Shiraiwa, Y., Yoshida, Y., Kozawa, J., & Shimomura, I. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1441-22 · Cited by 3
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
Wang, J., Xie, T., Zhang, Y., & Zhang, H. (2025) · Cardiorenal Medicine · doi:10.1159/000546238 · Cited by 2
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 3
“The retrieved studies were exported to Rayyan.ai, an online tool for duplicate identification and removal [15-23].”
Incorporating estimands into meta-analyses of clinical trials
Remiro‐Azócar, A., Polavieja, P., Boutmy, E., Ghiretti, A., Husemoen, L. L. N., Rantell, K. R., Vaitsiakhovich, T., Phillippo, D., Park, J., Lynggaard, H., et al. (2026) · Research Synthesis Methods · doi:10.1017/rsm.2026.10107 · Cited by 2
“In T2D, premature treatment discontinuation and the initiation of anti-diabetic rescue medication are well-established intercurrent events that should be accounted for, even in aggregate-level meta-analyses.”
Self-citationPostema, A., Gaspersz, J., Baak, B. N., Huisman, E. L., Hoogstraten, C., Hagelund, L. M., Beest, F. J. A. P., & Overbeek, J. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70251 · Cited by 2
Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet
Yoon, J.-H., Kim, D.-H., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040440 · Cited by 2
“Semaglutide (molecular weight: 4113.58 g/mol) is a peptide-based GLP-1 analog engineered via strategic amino acid modifications to enhance resistance to dipeptidyl peptidase-4-mediated enzymatic degradation and extend its biological half-life [6].”
InfluentialFrom the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Piraccini, B. M., Vaño-Galvan, S., Blume‐Peytavi, U., Ribet, V., & Mengeaud, V. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01792-0 · Cited by 2
Liu, M. N., Wang, X., Li, M., Yang, E., Yang, A., Yuan, M., Dong, R., Qin, G., Liu, P., Li, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102874 · Cited by 2
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
Escobar, C., Castro, A., Cerezo, J. F. G., Górriz, J. L., Obaya, J. C., & Villar‐Taibo, R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00013-9 · Cited by 7
Mohanan, P. P., & Jariwala, P. V. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.010 · Cited by 2
Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides
Saxena, T., Sie, C., Lin, K., Ye, D., Saatchi, K., & Häfeli, U. O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122809 · Cited by 3
“Semaglutide [35,36] Rybelsus® Induce insulin secretion Enzyme inhibitor, enteric coating, Absorption enhancer (SNAC) ˆ ~1%”
BackgroundKhamnueva, L. Y., & Андреева, Л. С. (2023) · Problems of Endocrinology · doi:10.14341/probl13245 · Cited by 3
Raddatz, D. (2023) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-023-00170-3 · Cited by 2
Current options for the treatment of obesity
Haluzík, M., Jakubíková, I., Kudláčková, M., & Horváth, L. (2023) · Medicína pro praxi · doi:10.36290/med.2023.036 · Cited by 2
Self-citationRosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
“…intensive Although subcutaneously administered glucose-lowering treatments typically show greater efficacy than orally administered alternatives, 15,19,20,24 – 26 in PIONEER 4, individuals on oral semaglu-tide 14 mg spent a similar amount of time with HbA1c less than 7.0% ( 53 mmol/mol) versus…”
BackgroundInfluentialSelf-citationGLP-1 RAs: The newest powerhouse in metabolic medicine
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Aoyama, K., Nakajima, Y., Meguro, S., & Hayashi, K. (2024) · Diabetology International · doi:10.1007/s13340-024-00744-3 · Cited by 2
Gudibanda, S., Govardhane, S., Kaloo, S., Shah, S., Miglani, V., & Verma, G. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_129_24 · Cited by 2
Bayesian analysis of the causal reference-based model for missing data in clinical trials
Nansereko, B., Wolbers, M., Carpenter, J. R., & Bartlett, J. W. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2654639 · Cited by 2
Development of mucosal absorption enhancers used biopharmaceuticals
Tamiwa, H., & Takeda‐Morishita, M. (2020) · Drug Delivery System · doi:10.2745/dds.35.10 · Cited by 2
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis
Bandyopadhyay, I., Dave, S., Rai, A., Nampoothiri, M., Chamallamudi, M. R., & Kumar, N. (2021) · Current Drug Targets · doi:10.2174/1389450122666210901125420 · Cited by 2
Die diabetische Angiopathie: Eine Synopse
Rittig, K. (2020) · Diabetes aktuell · doi:10.1055/a-1215-5503 · Cited by 2
“[21] Aroda VR, Rosenstock J, Terauchi Y et al.”
BackgroundLi, W. (2024) · Preprints.org · doi:10.20944/preprints202406.1032.v1 · Cited by 2
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.